Portillo's Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results Oak Brook, IL— February 24, 2026—Portillo's Inc. ("Portillo's" or the "Company") (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the fourth quarter and fiscal year ended December 28, 2025. Fourth Quarter 2025 Performance Highlights (vs. Fourth Quarter 2024): Fiscal 2025 Performance Highlights (vs. Fiscal 2024): (1) Adjusted EBITDA and Restau ...

Financial Performance - The net loss for 2025 was $12,879,000, compared to a net loss of $9,826,000 in 2024, representing an increase in loss of approximately 31.5%[375] - The company reported a total comprehensive loss of $12,949,000 for 2025, compared to $9,825,000 in 2024, reflecting a worsening financial position[375] - The accumulated deficit increased from $50,136,000 in 2024 to $63,015,000 in 2025, an increase of approximately 25.7%[373] - The company has incurred losses since inception, raising substantial doubt about its ability to continue as a going concern within one year after the issuance of the consolidated financial statements[394] - The company has a total accumulated deficit of $63,015,000 as of December 31, 2025[378] Assets and Liabilities - Total current assets decreased from $2,557,000 in 2024 to $695,000 in 2025, a decline of approximately 72.8%[373] - Total current liabilities increased from $1,772,000 in 2024 to $4,044,000 in 2025, an increase of approximately 128.3%[373] - The total liabilities increased from $1,841,000 in 2024 to $4,073,000 in 2025, an increase of approximately 121.3%[373] - Cash and cash equivalents decreased significantly from $2,338,000 in 2024 to $600,000 in 2025, a decline of approximately 74.3%[373] - Cash and cash equivalents decreased to $600,000 by the end of 2025, down from $2,338,000 at the beginning of the year, reflecting a net change of $1,738,000[380] Operating Expenses - Total operating expenses rose from $10,108,000 in 2024 to $11,404,000 in 2025, an increase of approximately 12.8%[375] - Research and development expenses totaled $5,423,000 for the year ended December 31, 2025, compared to $5,993,000 in 2024, reflecting a decrease of approximately 9.5%[427] - The company incurred stock-based compensation expenses of $1,142,000 in 2025, up from $818,000 in 2024, representing a 39% increase[380] - Total general and administrative expenses increased to $5,981,000 in 2025 from $4,115,000 in 2024, marking an increase of approximately 45.3%[426] - The company’s professional fees in research and development decreased to $3,666,000 in 2025 from $5,169,000 in 2024, a decline of approximately 29%[427] Shareholder Equity - Basic and diluted loss per common share for 2025 was $12.52, compared to $18.30 in 2024, indicating a decrease in loss per share[375] - The company’s additional paid-in capital increased from $53,194,000 in 2024 to $62,013,000 in 2025, an increase of approximately 16.8%[373] - The total number of outstanding shares was reduced from 3,280,000 to approximately 546,667 due to a one-for-six reverse stock split effective June 13, 2025[398] - The Company authorized 500,000,000 shares of common stock, with 2,018,746 shares issued and outstanding as of December 31, 2025, compared to 567,582 shares in 2024[440] Financing Activities - The company raised $6,151,000 from the issuance of common shares for cash during the year ended December 31, 2025, compared to $112,000 in the previous year[380] - The Company entered into a Sales Agreement to offer and sell up to $6.5 million of common stock, with 50,858 shares sold under this agreement for net proceeds of $442 during the year ended December 31, 2025[443] - The Company entered into an Equity Purchase Agreement with Square Gate Capital for up to $25 million in common stock purchases, with an option to increase by an additional $25 million[463] - The Company raised total gross proceeds of $1,425 from a private placement of common stock and warrants on June 26, 2025, with net proceeds of $1,079 after transaction costs[441] Debt and Interest - The Company issued convertible notes with an aggregate principal amount of $900, which can be converted into common stock at a conversion price of $7.74[433] - The convertible notes accrue interest at a rate of 12% per annum, increasing to 20% upon an Event of Default, with a maturity date set for 180 days after the closing of the Notes Offering[435] - The Company recorded interest expense of $278 for the year ended December 31, 2025, which includes $69 for accrued interest and $209 for amortization of deferred debt costs[437] Tax and Deferred Assets - As of December 31, 2025, the net deferred tax assets are $0, with a valuation allowance of $7,817 against NOL carryover of $7,817[458] - The Company has incurred an aggregate net operating loss of $37,780, with net operating loss carryforwards beginning to expire in varying amounts starting in 2034[456] Other Financial Information - The Company capitalized costs associated with acquiring an exclusive worldwide license for the compound ART27.13 as an intangible asset valued at $2,039 as of December 31, 2025[459] - The operating lease cost increased to $35 in 2025 from $32 in 2024, with cash paid for operating leases also rising to $35 from $30[462] - Future minimum lease payments under the operating lease liability total $73, with current liabilities of $40 and non-current liabilities of $29 as of December 31, 2025[462] - The Company is obligated to make additional payments related to research and development contracts based on progress and milestones achieved[465]

Exhibit 99.1 Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates ~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., February 24, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39942 Shoals Technologies Group, Inc. (Exact name of registrant as specified in its charter) | Delaware | ...

Exhibit 99.1 NRG Energy, Inc. Reports Full Year 2025 Financial Results HOUSTON—February 24, 2026—NRG Energy, Inc. (NYSE: NRG) today reported GAAP Net Income of $66 million for the three months ended December 31, 2025 and $0.9 billion for the full year 2025. GAAP EPS — basic was $4.09, Cash Provided by Operating Activities was $1.9 billion, Adjusted Net Income was $1.6 billion, Adjusted EPS was $8.24, Adjusted EBITDA was $4.1 billion, and Free Cash Flow before Growth (FCFbG) was $2.2 billion for the full yea ...

Exhibit 3.2 Amended and Restated Bylaws of Cipher Digital Inc. (a Delaware corporation) Table of Contents Article II - Meetings of Stockholders 1 Article III - Directors 12 Article IV - Committees 14 Article V - Officers 15 Page i 1.1. Registered Office. 1 1.2. Other Offices. 1 2.1. Place of Meetings. 1 2.2. Annual Meeting. 1 2.3. Special Meeting. 1 2.4. Notice of Business to be Brought before a Meeting. 1 2.5. Notice of Nominations for Election to the Board. 5 2.6. Notice of Stockholders' Meetings. 9 2.7. ...

Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance WALTHAM, Mass., February 24, 2026 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve- month periods ended December 31, 2025. The Company is also providing financ ...

Exhibit 99.1 FIS Reports Full-Year 2025 Results and Introduces 2026 Outlook JACKSONVILLE, Fla., February 24, 2026 - FIS (NYSE:FIS), a global leader in financial technology, today reported its fourth quarter and full-year 2025 results. ® "We are entering 2026 with continued strong momentum as our commercial excellence initiatives and investments in innovation are driving durable revenue growth and expanding margins," said FIS CEO and President Stephanie Ferris. "With the Issuing acquisition, FIS now operates ...

| (In millions, except per share amounts) | | Fourth Quarter | | Full Year | | | | --- | --- | --- | --- | --- | --- | --- | | | 2025 | 2024 | Change | 2025 | 2024 | Change | | Revenues | $1,060 | $981 | 8% | $3,648 | $3,234 | 13% | | Net Earnings | $102 | $89 | 15% | $278 | $213 | 31% | | Diluted weighted average number of shares | | | | | | | | outstanding (WASO) | 268.423 | 268.955 | | 268.726 | 267.733 | | | Diluted Earnings Per Share | | | | | | | | (EPS) | $0.38 | $0.33 | 15% | $1.03 | $0.80 | 29% | | ...

EXHIBIT 99.1 WESTLAKE CORPORATION Contact—(713) 960-9111 Investors—Steve Bender Media—L. Benjamin Ederington Westlake Corporation Reports Fourth Quarter and Full Year 2025 Results • Meaningful actions taken in 2025 to optimize footprint, improve plant reliability, and structurally reduce costs expected to provide earnings improvement in 2026 HOUSTON--(BUSINESS WIRE)--Westlake Corporation (NYSE: WLK) (the "Company" or "Westlake") today announced fourth quarter and full year 2025 results. i SUMMARY FINANCIAL ...